PATENT CLAIM ANALYSIS

Application Number: 16069585
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["514", "215000"]

Abstract:
The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R 1 , R 2 , R 3 , R 4 , R 5 , a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.

Claim (Index 7):
The compound of  claim 6  wherein\n A is \n or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 95.0
- Lexical Diversity: 1.72603
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12532715', '15423238', '11752683', '14157671', '12162851']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7791515314039287
- 35 USC 102 Novelty (BERT): 0.532292945278935
- Combined Prediction Score: 0.7544656727914293
- Mean Citation Score: 336.6946460000001
- Max Citation Score: 341.11978
- Similarity Product: 265.13941270446657

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test